Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

TITLE:
Phase 3, Multicenter, Open-label Study to Assess the Long-term Safety and Tolerability of Rimegepant for the Acute Treatment of Migraine (With or Without Aura) in Children and Adolescents ≥ 6 to < 18 Years of Age
MEDICAL CONDITION: Acute Treatment of Migraine
AGE: 6-17yrs
SEX/GENDER: All

OVERVIEW

The purpose of this study is to test the long-term safety of rimegepant in the acute treatment of moderate or severe migraine in children and adolescents (≥ 6 to < 18 years of age).

STUDY DETAILS

Inclusion Criteria:

  1. History of migraine (with or without aura) for ≥ 6 months before Screening
  2. History of 1 to 8 moderate or severe attacks per month during the 2 months prior to enrollment.
  3. 1 or more migraine days requiring treatment during the Observation Phase.
  4. Prophylactic migraine medication is permitted if the dose has been stable for at least 12 weeks prior to the Baseline Visit
  5. Ability to distinguish between migraine and other types of headaches.
  6. Weight ≥ 40 kg at the Screening Visit.
  7. Adequate venous access for blood sampling.
  8. Male and female participants ≥ 6 to < 18 years of age (participants must not reach their 18th birthday before enrollment into the study)

Exclusion Criteria:

  1. History of cluster headache or hemiplegic migraine headache.
  2. Confounding and clinically significant pain syndrome
  3. Current uncontrolled and/or untreated psychiatric condition for a minimum of 6 months prior to the Screening Visit (lifetime history of psychosis and/or mania are excluded).
  4. History of suicidal behavior or major psychiatric disorder.
  5. Current diagnosis or history of substance abuse; positive drug test at Screening.